James Parsons - DiaMedica Therapeutics Director
| DMAC Stock | USD 2.49 0.11 4.23% |
Director
Mr. James T. Parsons, CPA., CA., is Director of the Company. He was Corporationrationrate Secretary of the Company. He joined company as Corporationrationrate Secretary of DiaMedica Inc. He resigned from the position of Vice President Finance of the Company with effect from 15 January 2015. Mr. Parsons joined DiaMedica in October 2010 with an background in the life sciences industry and over 20 years of financial management experience. Prior to joining DiaMedica, Mr. Parsons was the Chief Financial Officer and Corporationrationrate Secretary for Amorfix Life Sciences Ltd. where his responsibilities included finance, administration, contract management, and corporate governance. Mr. Parsons was a CFO in the life sciences industry since 2000 with earlystage to lateclinical stage biotechnology companies across many diagnostic and therapeutic service areas. He is also currently the Chief Financial Officer of Stem Cell Therapeutics Corporationrationsince August 2011 since 2018.
| Tenure | 6 years |
| Address | 301 Carlson Parkway, Minneapolis, MN, United States, 55305 |
| Phone | 763 496 5454 |
| Web | https://www.diamedica.com |
James Parsons Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Parsons against DiaMedica Therapeutics stock is an integral part of due diligence when investing in DiaMedica Therapeutics. James Parsons insider activity provides valuable insight into whether DiaMedica Therapeutics is net buyers or sellers over its current business cycle. Note, DiaMedica Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell DiaMedica Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Parsons over three weeks ago Acquisition by James Parsons of 16773 shares of DiaMedica Therapeutics at 3.58 subject to Rule 16b-3 | ||
James Parsons over three months ago Acquisition by James Parsons of 21428 shares of DiaMedica Therapeutics subject to Rule 16b-3 | ||
James Parsons over six months ago DiaMedica Therapeutics exotic insider transaction detected |
DiaMedica Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3002) % which means that it has lost $0.3002 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4677) %, meaning that it created substantial loss on money invested by shareholders. DiaMedica Therapeutics' management efficiency ratios could be used to measure how well DiaMedica Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, DiaMedica Therapeutics' Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 56.4 M, whereas Non Currrent Assets Other are forecasted to decline to (0.94).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Linda Hohol | Oncolytics Biotech | 65 | |
| Srinivas Akkaraju | aTyr Pharma | 47 | |
| Mason Freeman | Scpharmaceuticals | 66 | |
| Mark Lievonen | Oncolytics Biotech | N/A | |
| Svetlana Lucas | aTyr Pharma | N/A | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| Deborah Brown | Oncolytics Biotech | N/A | |
| Wayne Rothbaum | Iovance Biotherapeutics | 50 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
| Richard Kender | Seres Therapeutics | 62 | |
| Angela Holtham | Oncolytics Biotech | N/A | |
| Edwin Levy | Oncolytics Biotech | N/A | |
| Timothy Coughlin | aTyr Pharma | 51 | |
| Werner Cautreels | Seres Therapeutics | N/A | |
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Kathryn Falberg | aTyr Pharma | 54 | |
| Sarah Payne | Terns Pharmaceuticals | 41 | |
| Michael Weiser | Iovance Biotherapeutics | 55 | |
| Merrill McPeak | Iovance Biotherapeutics | 82 | |
| Dennis Ausiello | Seres Therapeutics | 72 | |
Management Performance
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.3 |
DiaMedica Therapeutics Leadership Team
Elected by the shareholders, the DiaMedica Therapeutics' board of directors comprises two types of representatives: DiaMedica Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DiaMedica. The board's role is to monitor DiaMedica Therapeutics' management team and ensure that shareholders' interests are well served. DiaMedica Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DiaMedica Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Papi, Vice President - Business Development | ||
| James Parsons, Director | ||
| Ambarish Shah, Chief Officer | ||
| Richard Pilnik, Independent Chairman of the Board | ||
| Julie CCRP, Senior Operations | ||
| Jerry Xiao, Director | ||
| Dominic Cundari, Chief Officer | ||
| David Wambeke, Chief Officer | ||
| Scott CPA, CFO Secretary | ||
| Todd Verdoorn, Chief Scientific Officer | ||
| MS MD, Independent Consultant | ||
| Scott CA, CFO Sec | ||
| Edward Calamai, Consulting Manufacturing | ||
| Scott Kellen, CFO, Corporate Secretary | ||
| Michael Giuffre, Independent Director | ||
| Lorianne MD, Chief Officer | ||
| Dietrich MBA, CEO President | ||
| Rick Pauls, President CEO, Director | ||
| Harry Alcorn, Director |
DiaMedica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DiaMedica Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 42.02 M | ||||
| Shares Outstanding | 37.96 M | ||||
| Shares Owned By Insiders | 26.65 % | ||||
| Shares Owned By Institutions | 22.01 % | ||||
| Number Of Shares Shorted | 202.17 K | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 1.80 X | ||||
| EBITDA | (21.24 M) |
Pair Trading with DiaMedica Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DiaMedica Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to DiaMedica Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DiaMedica Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DiaMedica Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DiaMedica Therapeutics to buy it.
The correlation of DiaMedica Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DiaMedica Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DiaMedica Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DiaMedica Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Return On Assets (0.30) | Return On Equity (0.47) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.